Clinical Outcomes of CD19 NEX-T CAR T Cell Therapy

This technical report presents the pooled safety analysis and preliminary efficacy results of zola-cel (BMS-986353), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, in patients with severe refractory autoimmune diseases. The report details findings from the phase 1 Breakfree studies, which evaluated the therapy's safety and tolerability, as well as its potential to achieve disease control in conditions such as systemic lupus erythematosus, relapsing multiple sclerosis, and myasthenia gravis. The NEX-T manufacturing process, which allows for a shorter production time while maintaining product quality, is also discussed. The report includes demographic data, treatment protocols, and the safety profile of zola-cel, highlighting the manageable nature of cytokine release syndrome and neurotoxicity events. Overall, the findings suggest that zola-cel may offer a new therapeutic option for patients with autoimmune diseases who have not responded to existing treatments.